OrsoBio is developing novel therapies to treat patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and more.
connect@orsobio.com
© 2023 OrsoBio, Inc. | Privacy Policy - FCOI Policy
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
